𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Levodopa dosage determines adherence to long-acting dopamine agonists in Parkinson's disease

✍ Scribed by Diego Santos-García; María Prieto-Formoso; Raúl de la Fuente-Fernández

Book ID
119304474
Publisher
Elsevier Science
Year
2012
Tongue
English
Weight
195 KB
Volume
318
Category
Article
ISSN
0022-510X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term tolerability and efficacy of c
Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease
✍ R. Inzelberg; P. Nisipeanu; M. J. Rabey; Prof. A. D. Korczyn 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 333 KB 👁 2 views

## Abstract Motor fluctuations constitute a severe complication of chronic levodopa therapy. The addition of dopamine agonists may partially alleviate these responses; however, due to the short half‐lefe of these drugs, several daily doses are required. Cabergoline is a new dopamine agonist with a

Hiccup secondary to dopamine agonists in
Hiccup secondary to dopamine agonists in Parkinson's Disease
✍ Jacobo Lester; Gabriela Beatriz Raina; Claudia Uribe-Roca; Federico Micheli 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 45 KB 👁 1 views

Hiccup is produced by a sudden contraction of the inspiratory muscles followed by an abrupt closure of the glottis, which produces the typical sound that characterizes this disorder. The causes of hiccup are diverse, 1 including several drugs. 2 Here, we report two cases of patients with Parkinson's